Gene expression changes in tumor following ADH-503 treatment
Ontology highlight
ABSTRACT: To understand the effect of ADH-503, we have employed microarray expression profiling to identify genes that change at different times 48hrs and 10 days after treatment initiation. CD11b/18 (alphaMbeta2), an integrin molecule is highly expressed on all myeloid cells and plays an important role in transendothelial migration and functional changes in these cells. Here we demonstrate that a small molecule agonist of CD11b, ADH-503 was associated reprograming tumor immunity by promoting anti-tumor immune cell populations by enhancing antigen presentation by macrophages and cDCs and together these changes resulted in stabilization of tumor growth and improvement in overall survival.
ORGANISM(S): Mus musculus
PROVIDER: GSE127258 | GEO | 2019/02/28
REPOSITORIES: GEO
ACCESS DATA